Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.

Multiple myeloma is a bone marrow-based plasma cell tumour that develops from asymptomatic pre-cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclonal protein in the blood. Diagnosis and distinction between these conditions is based on blood tests, the bone marrow biopsy and cross sectional imaging. There are various risk stratification models that group patients with smouldering myeloma into risk groups based on risk of progression to symptomatic disease. Management is mainly observational for patients with smouldering myeloma although clinical trials for high-risk disease may be available. Restaging is required if evidence for progression.

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.

PURPOSE: Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematological malignancies (NCT01943851). PATIENTS AND METHODS: Part 1 (dose escalation) determined the recommended Phase 2 dose (RP2D) of molibresib in patients with acute myeloid leukemia (AML), Non-Hodgkin lymphoma (NHL), or multiple myeloma. Part 2 (dose expansion) investigated the safety and efficacy of molibresib at the RP2D in patients with relapsed/refractory myelodysplastic syndrome (MDS; as well as AML evolved from antecedent MDS) or cutaneous T-cell lymphoma (CTCL). The primary endpoint in Part 1 was safety and the primary endpoint in Part 2 was objective response rate (ORR). RESULTS: There were 111 patients enrolled (87 in Part 1, 24 in Part 2). Molibresib RP2Ds of 75 mg daily (for MDS) and 60 mg daily (for CTCL) were selected. Most common Grade 3+ adverse events included thrombocytopenia (37%), anemia (15%), and febrile neutropenia (15%). Six patients achieved complete responses [3 in Part 1 (2 AML, 1 NHL), 3 in Part 2 (MDS)], and 7 patients achieved partial responses [6 in Part 1 (4 AML, 2 NHL), 1 in Part 2 (MDS)]. The ORRs for Part 1, Part 2, and the total study population were 10% [95% confidence interval (CI), 4.8-18.7], 25% (95% CI, 7.3-52.4), and 13% (95% CI, 6.9-20.6), respectively. CONCLUSIONS: While antitumor activity was observed with molibresib, use was limited by gastrointestinal and thrombocytopenia toxicities. Investigations of molibresib as part of combination regimens may be warranted.

Clinical profile and outcome of neonatal pneumothorax in resource-limited neonatal intensive care unit.

OBJECTIVE OF STUDY: To determine the frequency, clinical profile, and outcome of pneumothoraxes in neonates in resource-limited neonatal intensive care unit (NICU) setting. STUDY DESIGN: Prospective cohort. PLACE AND DURATION OF STUDY: The study was carried over a period of 4 years and 6 months at two NICUs of Combined Military Hospital (CMH) Multan (January 2011-August 2013) and CMH Abbottabad (September 2013-July 2015). MATERIALS AND METHODS: All neonates fulfilling inclusion criteria were included in the study. Demographic and clinical parameters were recorded. All stable cases were initially managed on headbox oxygen, nasal oxygen, or improvised bubble continuous positive airway pressure devices (B-CPAP). In suspected cases, pneumothorax was confirmed on a portable chest X-Ray (CXR). Hemodynamically stable neonates were closely observed for spontaneous resolution whereas unstable neonates were managed by needle thoracocentesis or thoracostomy with or without ventilator support. End point of the study was either discharge or death of the neonate. RESULTS: Of a total of 1427 included neonates, 66 (4.6%) developed pneumothorax. Pneumothorax was more common in late pre-term and term infants with normal birth weight (>2.5 kg). Primary diseases leading to pneumothorax were respiratory distress syndrome (RDS) 38 (57.6%), meconium aspiration syndrome (MAS) 10 (15.2%), transient tachypnea of newborn (TTN) 9 (13.6%), birth asphyxia syndrome (BAS) 6 (9.1%), and pneumonia 3 (4.5%). Majority of the patients 58 (87.9%), required thoracostomy, 2 (3%) required only needle thoracocentesis while spontaneous resolution occurred in 6 (9.1%) patients. Out of 66 patients, 48 (72.7%) were discharged and 18 (27.3%) died. Average hospital stay was 10.5 ± 5.85 days. CONCLUSION: Pneumothorax is not an uncommon complication in neonates presenting with respiratory distress in resource-limited NICUs. High index of suspicion is required for early recognition and timely management, as delay is associated with significant mortality.

Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression.

Altered transcription is a cardinal feature of acute myeloid leukemia (AML); however, exactly how mutations synergize to remodel the epigenetic landscape and rewire three-dimensional DNA topology is unknown. Here, we apply an integrated genomic approach to a murine allelic series that models the two most common mutations in AML: Flt3-ITD and Npm1c. We then deconvolute the contribution of each mutation to alterations of the epigenetic landscape and genome organization, and infer how mutations synergize in the induction of AML. Our studies demonstrate that Flt3-ITD signals to chromatin to alter the epigenetic environment and synergizes with mutations in Npm1c to alter gene expression and drive leukemia induction. These analyses also allow the identification of long-range cis-regulatory circuits, including a previously unknown superenhancer of Hoxa locus, as well as larger and more detailed gene-regulatory networks, driven by transcription factors including PU.1 and IRF8, whose importance we demonstrate through perturbation of network members.

Mouse Models of Myeloid Malignancies.

Mouse models of human myeloid malignancies support the detailed and focused investigation of selected driver mutations and represent powerful tools in the study of these diseases. Carefully developed murine models can closely recapitulate human myeloid malignancies in vivo, enabling the interrogation of a number of aspects of these diseases including their preclinical course, interactions with the microenvironment, effects of pharmacological agents, and the role of non-cell-autonomous factors, as well as the synergy between co-occurring mutations. Importantly, advances in gene-editing technologies, particularly CRISPR-Cas9, have opened new avenues for the development and study of genetically modified mice and also enable the direct modification of mouse and human hematopoietic cells. In this review we provide a concise overview of some of the important mouse models that have advanced our understanding of myeloid leukemogenesis with an emphasis on models relevant to clonal hematopoiesis, myelodysplastic syndromes, and acute myeloid leukemia with a normal karyotype.

Genome-scale drop-out screens to identify cancer cell vulnerabilities in AML.

Acute myeloid leukemia (AML) is an aggressive cancer that remains lethal to the majority of sufferers. Whilst the mainstay treatments for this condition have remained largely unchanged over the past five decades, progress in deciphering its pathogenesis has accelerated in recent years, propelled in part by advances in cancer genomics and mechanistic studies of leukemogenic mutations. Newer molecular therapies targeting aberrant biological pathways are currently under investigation with a few moving closer to clinical use. However, collectively, these new therapies are not predicted to have a major impact on clinical outcomes and the need for the identification of further therapeutic targets in AML remains critical. Recently the use of CRISPR-Cas9 systems for genome editing and their potential application in genome-wide screening has opened a new frontier for unbiased discovery of therapeutic vulnerabilities in cancer and AML was the first disease in which this technology was systematically applied. In this review we give an overview of recent advances in identifying novel therapeutic vulnerabilities of AML using CRISPR-Cas9 and discuss possible future applications of CRISPR technologies in this field.

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.

Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the evolution of acute myeloid leukemia (AML), where we observed stage-specific and diametrically opposite functions for Ezh2 at the early and late stages of disease. During disease maintenance, WT Ezh2 exerts an oncogenic function that may be therapeutically targeted. In contrast, Ezh2 acts as a tumor suppressor during AML induction. Transcriptional analysis explains this apparent paradox, demonstrating that loss of Ezh2 derepresses different expression programs during disease induction and maintenance. During disease induction, Ezh2 loss derepresses a subset of bivalent promoters that resolve toward gene activation, inducing a feto-oncogenic program that includes genes such as Plag1, whose overexpression phenocopies Ezh2 loss to accelerate AML induction in mouse models. Our data highlight the importance of cellular context and disease phase for the function of Ezh2 and its potential therapeutic implications.

Frequency Of Congenital Hearing Loss In Neonates.

BACKGROUND: Congenital deafness is commonest birth defect and it affects 2-4 neonates among 1000 live births. Detection and intervention especially before 6 months of age prevents severe linguistic, educational and psychosocial repercussions and helps the deaf child in the development of normal speech and language. Children who are identified after 6 months of age experience great difficulties in attaining speech and language.. METHODS: To find out the frequency of hearing loss in neonates, a hospital based observational study was conducted in Combined Military Hospital Abbottabad from June-to December 2014. One thousand new-borns selected by consecutive sampling within a specified period of time were subjected to Otoacoustic Emission (OAE) testing. Brain Evoked Response Audiometry (BERA) evaluation was performed in all those who failed OAE testing to confirm the hearing loss. Children born with microtia, meatal stenosis, cleft palate, craniofacial abnormalities and syndromic illnesses were excluded from the study. RESULTS: Of 1000 new-borns screened, 465 were males and 535 were females whereas 632 (63.2%) were delivered through C-section and 368 (36.8%) were born via SVD. Four hundred and ninety-one (49%) babies had a positive history of consanguinity among the parents. Out of 1000 infants 13 were having hearing loss which was later on confirmed on BERA evaluation. Among them 7 were males and 6 females, 9 (69%) were born through SVD and 4 (31%) through C-section and 8 (61.5%) new-borns had a positive history of consanguinity among their parents. In all these 13 patients only 2 (15%) patients had profound while the remaining 11 (85%) had moderate to severe hearing loss. CONCLUSIONS: Frequency of hearing loss in neonates is much higher in our study (13 per 1000) as compared to other parts of the world and demands that more studies should be undertaken on this subject to confirm this.

Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.

FLT3 internal tandem duplication (FLT3ITD) mutations are common in acute myeloid leukemia (AML) associated with poor patient prognosis. Although new-generation FLT3 tyrosine kinase inhibitors (TKI) have shown promising results, the outcome of FLT3ITD AML patients remains poor and demands the identification of novel, specific, and validated therapeutic targets for this highly aggressive AML subtype. Utilizing an unbiased genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 screen, we identify GLS, the first enzyme in glutamine metabolism, as synthetically lethal with FLT3-TKI treatment. Using complementary metabolomic and gene-expression analysis, we demonstrate that glutamine metabolism, through its ability to support both mitochondrial function and cellular redox metabolism, becomes a metabolic dependency of FLT3ITD AML, specifically unmasked by FLT3-TKI treatment. We extend these findings to AML subtypes driven by other tyrosine kinase (TK) activating mutations and validate the role of GLS as a clinically actionable therapeutic target in both primary AML and in vivo models. Our work highlights the role of metabolic adaptations as a resistance mechanism to several TKI and suggests glutaminolysis as a therapeutically targetable vulnerability when combined with specific TKI in FLT3ITD and other TK activating mutation-driven leukemias.

Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.

Loss-of-function mutations of cyclic-AMP response element binding protein, binding protein (CREBBP) are prevalent in lymphoid malignancies. However, the tumour suppressor functions of CREBBP remain unclear. We demonstrate that loss of Crebbp in murine haematopoietic stem and progenitor cells (HSPCs) leads to increased development of B-cell lymphomas. This is preceded by accumulation of hyperproliferative lymphoid progenitors with a defective DNA damage response (DDR) due to a failure to acetylate p53. We identify a premalignant lymphoma stem cell population with decreased H3K27ac, which undergoes transcriptional and genetic evolution due to the altered DDR, resulting in lymphomagenesis. Importantly, when Crebbp is lost later in lymphopoiesis, cellular abnormalities are lost and tumour generation is attenuated. We also document that CREBBP mutations may occur in HSPCs from patients with CREBBP-mutated lymphoma. These data suggest that earlier loss of Crebbp is advantageous for lymphoid transformation and inform the cellular origins and subsequent evolution of lymphoid malignancies.

BET bromodomain inhibitors in leukemia.

The last few years have seen the identification of bromodomain and extraterminal (BET) proteins as critical mediators of transcription with effects on its direct control and cisregulation. This discovery is important in furthering our understanding of the mechanisms of normal transcriptional control. Subsequent work has shed light on the multiple roles of BET proteins in various aberrant transcriptional pathways that have significant implications across many malignant cell types and other disease processes. Accordingly, considerable effort has been made to assess the utility of targeting BET proteins with specific small molecules in acute leukemia and across other types of cancer. In this review, we will discuss the most recent advances in our understanding of the mechanistic actions of BET proteins in normal transcriptional control, both at the gene body and cisregulatory elements; how this is subverted; and its aberrant downstream effects, specifically in the context of acute leukemia and other hematologic cancers. In particular, we will focus on altered epigenetic programs that have been shown to be central to the development and maintenance of acute myeloid leukemia in preclinical models. Finally, we will explore how the use of small-molecule BET inhibitors in leukemias has demonstrated significant promise in numerous single-agent and combination therapy preclinical models and will highlight efforts to translate this promise to the therapeutic arena through various clinical trials attempting to validate efficacy and safety. The considerable opportunities in epigenetically targeting leukemias through BET inhibition will undoubtedly play an important role in improving the management of these conditions in the future.

Branchio-oto-renal syndrome.

The association of branchial arch anomalies (branchial cysts, branchial fistulas), hearing loss and renal anomalies constitutes the branchio-oto-renal (BOR) syndrome also known as Melnick Fraser syndrome. We present a case of this rare disorder in a girl child who presented with profound deafness, preauricular pits, branchial sinuses and renal hypoplasia.

Hairy cell leukemia - immunotargets and therapies.

Hairy cell leukemia (HCL) is an indolent low-grade B-cell lymphoproliferative disorder that is reasonably sensitive to standard first-line purine analog therapy. However, in many cases, repeat relapses occur, requiring multiple courses of purine analog therapy, promoting eventual drug resistance. This, coupled with the concerning side effects of repeated purine analog exposure, has prompted the search for alternative targets and therapies that may provide deeper remissions. Novel strategies employing immune-mediated targeting via monoclonal antibody therapies and recombinant immunotoxins appear promising in HCL and are currently under investigation. More recently, the concept of targeted kinase inhibition using small-molecule inhibitors in HCL has emerged as another potentially viable option. As a deeper understanding of the aberrant molecular pathways contributing to the pathogenesis of HCL develops, the landscape of management for HCL, particularly in the relapse setting, may change significantly in the future as a result of these promising immunotargets and therapies.

Cholangiocarcinoma presenting as hemobilia and recurrent iron-deficiency anemia: a case report.

INTRODUCTION: Iron-deficiency anemia is a relatively common presenting feature of several gastrointestinal malignancies. However, cholangiocarcinoma has rarely been reported as an underlying cause. The association of cholangiocarcinoma with the rare clinical finding of hemobilia is also highly unusual. To our knowledge, this is the first case report of cholangiocarcinoma presenting with acute hemobilia and chronic iron-deficiency anemia. CASE PRESENTATION: We report the case of a Caucasian, 84-year-old woman presenting with recurrent, severe iron-deficiency anemia who was eventually diagnosed with intra-hepatic cholangiocarcinoma, following an acute episode of hemobilia. A right hepatectomy was subsequently performed with curative intent, and our patient has now fully recovered. CONCLUSION: This is a rare example of hemobilia and chronic iron-deficiency anemia in association with cholangiocarcinoma. We suggest that a diagnosis of cholangiocarcinoma should be considered in patients who present with iron-deficiency anemia of unknown cause, particularly in the presence of abnormal liver function.